Terence Flotte to Gene Editing
This is a "connection" page, showing publications Terence Flotte has written about Gene Editing.
Connection Strength
6.260
-
Gruntman AM, Xue W, Flotte TR. Approaches to Therapeutic Gene Editing in Alpha-1 Antitrypsin Deficiency. Methods Mol Biol. 2024; 2750:11-17.
Score: 0.630
-
Batista AR, Flotte TR. In?vivo gene editing works in humans: Results of a phase 1 clinical trial for TTR amyloidosis. Mol Ther. 2021 09 01; 29(9):2633-2634.
Score: 0.535
-
Flotte TR. Base Editing to the Rescue. Hum Gene Ther. 2021 Jul; 32(13-14):647-648.
Score: 0.530
-
Flotte TR. CRISPR Keeps Things Fresh: Next-Generation Tools for Gene Editing. Hum Gene Ther. 2021 03; 32(5-6):235-236.
Score: 0.518
-
Flotte TR. Writing the Story of Gene Editing and CRISPR: An Interview with Kevin Davies, PhD. Hum Gene Ther. 2020 12; 31(23-24):1217-1220.
Score: 0.509
-
Flotte TR, Gao G. Prime Editing: A Novel Cas9-Reverse Transcriptase Fusion May Revolutionize Genome Editing. Hum Gene Ther. 2019 12; 30(12):1445-1446.
Score: 0.475
-
Flotte TR. Epigenome Editing Strategies for Low Back Pain. Hum Gene Ther. 2019 09; 30(9):1037-1038.
Score: 0.467
-
Flotte TR. Senior Gene Therapy Scientists Take a Stand Against Human Embryo Gene Editing. Hum Gene Ther. 2019 07; 30(7):793.
Score: 0.461
-
Flotte TR. Alpha-1 Antitrypsin Deficiency as a Candidate for Gene Editing. Hum Gene Ther. 2018 08; 29(8):843-844.
Score: 0.433
-
Keeler AM, ElMallah MK, Flotte TR. Gene Therapy 2017: Progress and Future Directions. Clin Transl Sci. 2017 07; 10(4):242-248.
Score: 0.399
-
Bamidele N, Pires-Ferreira D, Zheng C, Destefano A, Cheng H, Tang Q, Cao Y, Xie J, Gao G, Gruntman A, Sontheimer E, Flotte TR, Xue W. A compact base editor rescues AATD-associated liver and lung disease in mouse models. Mol Ther. 2025 Nov 05; 33(11):5817-5828.
Score: 0.177
-
Liang SQ, Navia AW, Ramseier M, Zhou X, Martinez M, Lee C, Zhou C, Wu J, Xie J, Su Q, Wang D, Flotte TR, Anderson DG, Tarantal AF, Shalek AK, Gao G, Xue W. AAV5 Delivery of CRISPR/Cas9 Mediates Genome Editing in the Lungs of Young Rhesus Monkeys. Hum Gene Ther. 2024 10; 35(19-20):814-824.
Score: 0.163
-
Gruntman AM, Xue W, Flotte TR. Alpha-1 Antitrypsin Deficiency. Methods Mol Biol. 2024; 2750:1-7.
Score: 0.158
-
Pires Ferreira D, Gruntman AM, Flotte TR. Gene therapy for alpha-1 antitrypsin deficiency: an update. Expert Opin Biol Ther. 2023 03; 23(3):283-291.
Score: 0.149
-
Flotte TR, Gessler DJ. Gene Therapy for Rare Neurological Disorders. Clin Pharmacol Ther. 2022 04; 111(4):743-757.
Score: 0.139
-
Liu P, Liang SQ, Zheng C, Mintzer E, Zhao YG, Ponnienselvan K, Mir A, Sontheimer EJ, Gao G, Flotte TR, Wolfe SA, Xue W. Improved prime editors enable pathogenic allele correction and cancer modelling in adult mice. Nat Commun. 2021 04 09; 12(1):2121.
Score: 0.130
-
Dasgupta I, Flotte TR, Keeler AM. CRISPR/Cas-Dependent and Nuclease-Free In Vivo Therapeutic Gene Editing. Hum Gene Ther. 2021 03; 32(5-6):275-293.
Score: 0.129
-
Flotte TR. Top Five Gene Therapy Stories of 2019. Hum Gene Ther. 2019 01; 30(1):1-2.
Score: 0.111
-
Gruntman AM, Flotte TR. Therapeutics: Gene Therapy for Alpha-1 Antitrypsin Deficiency. Methods Mol Biol. 2017; 1639:267-275.
Score: 0.097
-
Song CQ, Wang D, Jiang T, O'Connor K, Tang Q, Cai L, Li X, Weng Z, Yin H, Gao G, Mueller C, Flotte TR, Xue W. In Vivo Genome Editing Partially Restores Alpha1-Antitrypsin in a Murine Model of AAT Deficiency. Hum Gene Ther. 2018 08; 29(8):853-860.
Score: 0.027
-
Borel F, Tang Q, Gernoux G, Greer C, Wang Z, Barzel A, Kay MA, Shultz LD, Greiner DL, Flotte TR, Brehm MA, Mueller C. Survival Advantage of Both Human Hepatocyte Xenografts and Genome-Edited Hepatocytes for Treatment of a-1 Antitrypsin Deficiency. Mol Ther. 2017 11 01; 25(11):2477-2489.
Score: 0.026